Reference number : 276-2022-2023-Q4-00233, amendment number : , agreement type : C, recipient legal name : Halucenex Life Sciences Incorporated|Halucenex Life Sciences Incorporated, recipient country : CA, recipient province : NS, recipient city : Windsor|Windsor, recipient postal code : B0N 2T0, program name english : REGI - Strategic Growth Initiative (SGI), program name french : CERI - Initiative de croissance stratégique (ICS), program purpose english : nan, program purpose french : nan, agreement title english : 222322, agreement title french : 222322, agreement number : 222322, agreement value : 50000.0, agreement start date : 2023-03-20, agreement end date : 2024-01-31, description english : Hire a clinical trial director, description french : Embaucher un directeur d’essai clinique, expected results english : nan, expected results french : nan, additional information english : The assistance type is Non-Repayable Contribution., additional information french : Le type d'aide est contribution non remboursable., owner organization : acoa-apeca, owner organization title : Atlantic Canada Opportunities Agency | Agence de promotion économique du Canada atlantique